Results from a first-in-humanphase 1 trial (NCT04262466) evaluating the efficacy and safety of IMC-F106C in patients with PRAME-positive metastatic/unresectable tumors showed a significant clinical benefit with the first PRAME×CD3 ImmTAC therapy, and could specifically fulfill unmet needs for patients with melanoma, according to Omid Hamid, MD.
Clinical Trials
Phase 2 data promising for choroidal melanoma therapy
CHICAGO — AU-011 helped preserve vision in patients with early-stage choroidal melanoma, according to a study presented at the American Academy of Ophthalmology meeting.
In Phase 3 Trial, Tumor-Infiltrating Cells Found Highly Effective in Advanced Melanoma
A phase 3 trial comparing tumor-infiltrating cells (TILs) and a checkpoint inhibitor for the treatment of advanced melanoma favored TILs for every end point.
Bexmarilimab Derives Overall Survival Benefit in PD-1 Blockade Refractory Melanoma
Results from the melanoma cohort of the phase 1/2 MATINS show the potential of bexmarilimab monotherapy and combined with other immunotherapies across solid tumors and hematologic malignancies.